Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication

Journal of Virology

Volumn 70, Issue 4, 1996, Pages 2146-2153

  Caliendo, Angela M ^a   Savara, Anu ^a   Donna, A N ^a   DeVore, Kimberly ^a   Kaplan, Joan C ^a   D'Aquila, Richard T ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; PHYTOHEMAGGLUTININ; RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ARTICLE; CELL STIMULATION; DNA STRAND BREAKAGE; DNA SYNTHESIS; DNA TEMPLATE; ENZYME INHIBITION; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; MONONUCLEAR CELL; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS REPLICATION;

EID: 0030004944     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.70.4.2146-2153.1996     Document Type: Article

References (57)

1. Adachi, A., H. E. Gendelman, F. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone J. Virol. 59:284-291.
2. Boucher, C. A. B., R. Van Leeuwen, P. Kellatn, P. Schipper, J. Tijnagel, J. M. A. Lange, and B. A. Larder. 1993. Effects of discontinuation of zidovudine treatment on zidovudine sensitisity of HIV-1 isolates. Antimicrob. Agents Chemother. 37:1525-1530.
3. Boyer, P. L., C. Tantillo, R. G. Nanni, J. Ding, E. Arnold, and S. H. Hughes. 1994 Sensitivity of wild type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length the sensitivity of drug resistant mutants does not Proc. Natl. Acad. Sci. USA 91: 4882-4886.
4. Bukrinsky, M. I., T. Stanwick, L. M. P. Dempsey, and M. Stevenson. 1991. Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science 254:423-427.
5. Chou, T.-C. 1991 The median-effect principle and the combination index for quantitation of synergism and antagonism, p. 61-98. In T.-C. Chou and D. Rideout (ed.), Synergism and antagonism in chemotherapy. Academic Press, San Diego, Calif.
6. Chow, Y.-K., M. S. Hirsch, D. P. Merrill, L. J. Bechtel, J. J. Eron, J. C. Kaplan. and R. T. D'Aquila. 1993. Use of evolutionary limitations of HIV-1 multi-drug resistance to optimize therapy. Nature (London) 361:650-654. (Correction, 364:679.)
7. Coffin, J. M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-489.
8. D'Aquila, R. T., V. A. Johnson, S. L. Welles, A. J. Japour, D. R. Kuritzkes, V. DeGruttola, P. S. Reichelderfer, R. W. Coombs, C. S. Crumpacker, J. O. Kahn, D. D. Richman, AIDS Clinical Trials Group Protocol 116B/117 Team, and the Virology Committee Resistance Working Group. 1995. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern. Med. 122:401-408.
9. D'Aquila, R. T., and W. C. Summers. 1989. HIV-1 reverse transcriptase/ ribonuclease H high level expression in E. coli from a plasmid constructed using the polymerase chain reaction. J. Acquired Immune Defic. Syndrome 2:579-587.
10. Eron, J. J., Y.-K. Chow, A. M. Caliendo, J. Videler, K. DeVore, T. P. Cooley, H. A. Liebman, J. C. Kaplan, M. S. Hirsch, and R. T. D'Aquila. 1993. pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo. Antimicrob. Agents Chemother. 37:1480-1487.
11. Eron, J. J., P. Gorczyca, J. C. Kaplan, and R. T. D'Aquila. 1992. Susceptibility testing by polymerase chain reaction DNA quantitation: a method to measure drug resistance of human immunodeficiency virus type 1 isolates. Proc. Natl. Acad. Sci. USA 89:3241-3245.
12. Gao, W.-Y., R. Agbaria, J. S. Driscoll, and H. Mitsuya. 1994. Divergent antihuman immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells. J. Biol. Chem. 269:12633-12638.
13. Gao, W.-Y., A. Cara, R. C. Gallo, and F. Lori. 1993. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc. Natl. Acad. Sci. USA 90:8925-8928
14. Gibbs, J. S., D. A. Regier, and R. C. Desrosiers. 1994. Construction and in vitro properties of HIV-1 mutants with deletions in "'nonessential" genes. AIDS Res. Hum. Retroviruses 10:343-350.
15. Hammer, S., C. Crumpacker, R. D'Aquila, B. Jackson, J. Lathey, D. Livnat, and R. Reichelderter. 1993. Use of virologic assays for detection of human immunodeficiency virus in clinical trials: recommendations of the AIDS Clinical Trials Group Virology Committee. J. Clin. Microbiol. 31:2557-2564.
16. Ho, D. D., A. Neumann, U. A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (London) 373:123-126.
17. Holodniy, M., L. Mole, D. Margolis, J. Moss, H. Dong, E. Boyer, M. Urdea, J. Kolberg, and S. Eastman. 1995. Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA: genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy. J. Virol. 69:3510-3516.
18. Huber, H. E., J. M. McCoy, J. S. Seehra, and C. C. Richardson. 1989. Human immunodeficiency virus 1 reverse transcriptase. J Biol. Chem. 264:4669-4678.
19. Jackson, J. B., R. W. Coombs, K. Sannerud, F. S. Rhame. and H. H. Balfour. 1988. Rapid and sensitive viral culture method for human immunodeficiency virus type 1. J. Clin. Microbiol 26:1416-1418.
20. Jacobo-Molina, A., J. Ding, R. G. Nanni, A. D. Clark, X. Lu, C. Tantillo, R. L. Williams, G. Kamer, A. L. Ferris, P. A. Clark, A. S. Hizi, S. H. Hughes, and E. Arnold. 1993. Crystal structure of HIV-1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc. Natl. Acad. Sci USA 90:6320-6324.
21. James, S. P. 1994. Measurement of basic immunologic characteristics of human mononuclear cells, p. 7.10.1-7.10.10. In J. E. Coligan, A. M. Kruisbeek, D. H. Margulics, E. M. Shevach, and W. Strober (ed.), Current Protocols in Immunology. John Wiley and Sons Inc., New York.
22. Japour, A. J., D. L. Mayers, V. A. Johnson, D. R. Kuritzkes, L. A. Beckett, J.-M. Arduino, J. Lane, R. J. Black, P. S. Reichelderfer, R. T. D'Aquila, and C. S. Crumpacker. 1993. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 37:1095-1101.
23. Japour, A. J., S. L. Welles, R. T. D'Aquila, V. A. Johnson, D. D. Richman, R. W. Coombs, P. S. Reicheiderfer, J. O. Kahn, C. S. Crumpacker, D. R. Kuritzkes, the AIDS Clinical Trials Group 116B/117 Study Team, and the Virology Committee Resistance Working Group. 1995 Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients following long-term zidovudine treatment. J Infect. Dis. 171:1172-1179.
24. Johnson, V. A., R. E. Byington, and J. C. Kaplan. 1990 Reverse transcriptase (RT) activity assay, p. 98-102. In A. Aldovim and B. Walker (ed.), Techniques in HIV research. Stockton Press, New York.
25. Johnson, V. A., D. P. Merrill, J. A. Videler, T.-C. Chou, R. E. Byington, J. J. Eron, R. T. D'Aquila, and M. S. Hirsch. 1991 Two-drug combinations of zidovudine. didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 isolates. J. Infect. Dis. 164:646-655
26. Gln2 as a primer in an in vitro primer-utilization assay. Proc. Natl. Acad. Sci USA 89:9652-9656.
27. Kohlstaedt, L. A., J. Wang, J. M. Friedman, P. A. Rice, and T. A. Steitz. 1992. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256:1783-1790.
28. Kunkel, T. A., J. D. Robert, and R. A. Zakour. 1987. Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol. 154:367-382.
29. Lacey, S. F., J. E. Reardon, E. S. Furfine, T. A. Kunkel, B. Katarzyne, K. A. Eckert, S. D. Kemp, and B. A. Larder. 1992. Biochemical studies of the reverse transcriptase and RNase H activities from human immunodeficiency virus strains resistant to 3′-azido-3′-deoxythymidine. J. Biol Chem. 267: 15789-15794.
30. Larder, B. A., G. Darby, and D. D. Richman. 1989. HIV with reduced sensitivity to AZT isolated during prolonged therapy. Science 243:1731-1734.
31. Larder, B. A., and S. D. Kemp. 1989. Multiple mutations in HIV-1 reverse transcriplase confer high-level resistance to AZT. Science 246:1155-1158
32. Larder, B. A., S. D. Kemp, and P. R. Harrigan. 1995. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696-699.
33. Loveday, C., S. Kaye, M. Tenant-Flowers, M. Semple, U. Aylifle, I. V. Weller, and R. S. Tedder. 1995. HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy. Lancet 345:820-834.
34. Majumdar, C., J. Abbotts, S. Broder, and S. H. Wilson. 1988. Studies on the mechanism of human immunodeficiency virus reverse transcriptase. J. Biol Chem. 263:15657-15665.
35. Martin, J. L., J. E. Wilson, R. L. Haynes, and P. A. Funnan. 1993. Mechanism of resistance of human immunodeficiency virus type 1 to 2′,3′-dideoxyinosine Proc. Natl. Acad. Sci. USA 90:6135-6139.
36. McDougal, J. S., A. Mawie, and S. P. Cort. 1985. Cellular tropism of the human retrovirus HTLV-III/LAV I: role of T cell activation and expression of the T4 antigen. J. Immunol. 135:3151-3162.
37. Najera, I., A. Holguin, M. E. Quinones-Mateu, M. A. Munoz-Fernandez, R. Najera, C. Lopez-Galindez, and E. Domingo. 1995 pol gene quasispecies of human immunodeficiency virus mutations associated with drug resistance in virus from patients undergoing no drug therapy. J. Virol. 69:23-31.
38. Najera, I., D. D. Richman, I. Olivares, J. M. Rojas, M. A. Peinado, M. Perucho, R. Najera, and C. Lopez-Galindez. 1994. Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates. AIDS Res. Hum. Retroviruses 10:1479-1488
39. Patterson, B. K., M. Till, P. Otto, C. Goolsby, M. R. L. Furtado, J. McBride, and S. M. Wolinsky. 1993. Detection of HIV-1 DNA and messenger RNA in individual cells by PCR-driven in situ hybridization and flow cytometry Science 260:976-979.
40. Rashtchian, A., G. W. Buchman, D. M. Schuster, and M. S. Beringer. 1992 Uracil DNA glycosylase-mediated cloning of PCR-amplified DNA: application to genomic and cDNA cloning Anal Biochem 206:91-97
41. Rashtchian, A., C. G. Thorton, and G. Heidecker. 1992. A novel method for site-directed mutagenesis using PCR and uracil DNA glycosylase. PCR Methods Appl. 2:124.
42. Ratner, L., A. Fischer, L. L. Jagodzinski, H. Mitsuya, R.-S. Liog, R. C. Gallo, and F. Wong-Staal. 1987. Complete nucleoside sequences of functional clones of the AIDS virus. AIDS Res Human Retroviruses 3:57-69.
43. Reardon, J. E., and W. H. Miller. 1990. Human immunodeficiency virus reverse transcriptase: substrate and inhibitor kinetics with thymidme 5′-triphosphate and 3′-azido-3′deoxythymidme 5′-triphosphate. J. Biol Chem 265:20302-20307.
44. Reddy, M. K., S. E. Weitzel, and P. H. von Hippel. 1992. Processive proofreading is intrinsic to T4 DNA polymerase. J. Biol. Chem. 267:14157-14166
45. Sambrook, J., E. Fritsch, and T. Maniatis. 1989. Molecular cloning a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
46. Schuurman, R., M. Nijhuis, R. van Leewen, P. Schipper, D. de Jong, P. Collis, S. Danner, A. J. Mulder, C. Loveday, C. Christopherson, et al. 1995 Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J. Infect Dis. 171:1441-1449.
47. Shirasaka, T., S. Chokekijchai, A. Yamada, G. Gosselin. J.-L. Imbach, and H. Mitsuya. 1995. Comparative analysis of anti-human immunodeficiency virus type 1 activities of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cells. Antimicrob. Agents Chemother 39: 2555-2559.
48. Spina, C., A. J. C. Guatelli, and D. D. Richman. 1995. Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro. J. Virol 69:2977-2988.
49. St. Clair, M. H., J. L. Martin, G. Tudor-Williams, M. C. Bach, C. L. Vavro, D. M. King, P. Kellam, S. D. Kemp, and B. A. Larder. 1991. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase Science 253:1557-1559.
50. Stevenson, M., T. L. Stanvrick, M. P. Dempsey, and C. A. Lamonica. 1990. HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J. 9:1551-1560.
51. + T cells arc infectible by human immunodeficiency virus but do nor release virus after activation J. Virol. 69:5659-5665.
52. Tantillo, C., J. Ding, A. Jacobo-Molina, R. G. Nanni, P. L. Boyer, S. H. Hughes, R. Pauwels, K. Andries, P. A. J. Janssen, and E. Arnold. 1994 Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase-implications for mechanisms of drug inhibition and resistance. J. Mol. Biol. 243:369-387.
53. von Schwedler, U., R. S. Kornbluth, and D. Trono. 1994. The nuclear localization signal of the matrix protein of human immunodeficiency virus type 1 allows the establishment of infection in macrophages and quiescent T cells Proc. Natl. Acad. Sci. USA 91:6992-6996.
54. Wei, X., S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Nowak, B. H. Hahn, M. S. Saag, and G. M. Shaw. 1995. Viral dynamics in human immunodeficiency virus type 1 infection Nature (London) 373:117-122.
55. Zack, J. A., S. J. Arrigo, S. R. Weitsman, A. S. Go, A. Haislip, and I. S. Chen. 1990. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile latent viral structure. Cell 61:213-222.
56. Zack, J. A., A. M. Haislip, and I. S. Y. Chen. 1992 Incompletely reverse-transcribed human immunodeficiency virus type I genomes in quiescent cells can function as intermediates in the retroviral life cycle J. Virol 66:1717-1725.
57. Zhang, D., A. M. Caliendo, J. J. Eron, K. M. DeVore, J. C. Kaplan, M. S. Hirsch, and R. T. D'Aquila. 1994. Resistance to 2′.3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 38:282-287.